Cantargia AB (STO:CANTA), a biotechnology company that develops antibody-based treatments for life-threatening diseases, reported on Monday the first interim data with antibody CAN04 in combination with chemotherapy in the ongoing phase IIa CANFOUR study.
The company said that the data show that by adding CAN04, response rates are higher than historical data using these standard first line chemotherapies alone. Four out of seven evaluable patients with metastatic pancreatic cancer (PDAC) and two out of three patients with metastatic non-small cell lung cancer (NSCLC), including one patient with complete response (CR), had objective responses.
No major side effects were observed apart from those expected with chemotherapy or CAN04, the company said and added that the recruitment in PDAC, which essentially follows communicated timelines, is expected to be completed in early second quarter 2020 for PDAC. Recruitment for NSCLC is expected to be complete in early third quarter 2020.
Göran Forsberg, CEO at Cantargia stated: "This early-stage analysis of safety and efficacy in patients with metastatic cancer is really exciting. Response rates are higher than historical data and includes a patient with complete response. This fits with the hypothesis that CAN04 can be synergistic with chemotherapy and counteract chemoresistance."
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma